This article is more than 5 years old. Information may no longer be current.
Study: IOP, medications reduced 1 year after implantation of two micro-bypass stents
Click Here to Manage Email Alerts
SAN FRANCISCO — IOP reduction of more than 10 mm Hg was sustained at 1 year in a study evaluating implantation of two Glaukos iStents in patients with open-angle glaucoma not controlled on one medication, a presenter said here.
“For us as glaucoma surgeons, this really does offer us hope that there may be a new surgical option that could be available to medically uncontrolled open-angle glaucoma patients in the future,” L. Jay Katz, MD, said at the American Glaucoma Society annual meeting.
Presenting 1-year data on the MIGS Study Group, a prospective single-arm open-label study, Katz said that 92% of 39 patients achieved the primary effectiveness endpoint of 20% or greater reduction in IOP at 12 months with no ocular hypotensive medications. A secondary outcome of IOP of 18 mm Hg or lower with no ocular hypotensive medications was also achieved by 92% of patients.
There was a profound drop, more than 40% below baseline, in two-thirds of the patients in the study, Katz said.
“Whether you had a phakic or a pseudophakic eye in this study with open-angle glaucoma that was not controlled with one medication, there was a pretty high chance of success with implantation of two iStents,” Katz said.
Disclosure: Katz is a medical monitor and consultant for Glaukos.